US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 26.000
  • -0.330-1.25%
Close Feb 27 16:00 ET
  • 26.000
  • 0.0000.00%
Post 17:55 ET
3.23BMarket Cap-12.81P/E (TTM)

Apellis Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Apellis Pharmaceuticals Q4 2024 Estimates Date

Currency：USDFeb 28, 2025

Estimate YoY
Revenue
197.91M
+35.21%
EPS
-0.39
+46.23%
Analyst Rating
Buy

Feb 27, 2025

Apellis Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 13 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 199.112M--
Feb 28, 20252024/Q4-- / 197.915M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 199.112M--
Feb 28, 20252024/Q4-- / 197.915M--
Nov 5, 20242024/Q3196.830M / 199.824M--
Aug 1, 20242024/Q2199.685M / 191.306M--
May 7, 20242024/Q1172.325M / 164.259M--

Unlock Free Earnings Estimates

Apellis Pharmaceuticals Earnings Reports

  • Apellis Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

    Nov 5, 2024 07:01 ET

  • Apellis Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

    Aug 1, 2024 07:07 ET

  • Apellis Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

    May 7, 2024 07:04 ET

  • Apellis Pharmaceuticals | 10-K/A: Annual report (Amendment)

    Feb 29, 2024 17:15 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
    AIPUY
    +21.48%
    Collegium Pharmaceutical
    COLL
    +0.25%
    SilverCrest Metals
    SILV
    0.00%
    Enerpac Tool
    EPAC
    -0.20%
    Halozyme Therapeutics
    HALO
    -0.38%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Feb 27, 2025

    Buy

    • Buy

      61.54%

    • Hold

      38.46%

    • Sell

      0.00%

    Price Target

    No Data

    Investment Theme Gene Editing
    Gene Editing
    Intraday-2.01%